Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280202 · ClinicalTrials.gov registry record
Detection of Genetic Markers of Lung Cancer
A clinical trial of Lung Cancer, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 6,000
- Enrollment target
- 1
- Study location
NCT00280202 is a study of Lung Cancer that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 6,000 participants, above the 921-participant average among 409 other Lung Cancer trials with a reported enrollment target (551% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00280202, a study of Lung Cancer, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Conditions Studied
Interventions
- PROCEDURE Biopsy of the major carinal area
- PROCEDURE Biopsy of abnormal & suspicious areas of the bronchial tree
- PROCEDURE Evaluation of the tumor for DNA mutations
- PROCEDURE Bronchoalveolar Lavage (BAL) for cytokine analysis
- PROCEDURE Correlation of flow cytometric & RT PCR for TNM stage
Study Locations (1)
Pennsylvania
- Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 1996-06 |
| Est. Completion | 2050-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280202
The ClinicalTrials.gov registry entry for NCT00280202 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 921-participant average among 409 other Lung Cancer trials with a reported enrollment target (551% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Biopsy of the major carinal area is the first listed.
NCT00280202 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00280202 about?
NCT00280202 is a clinical study titled "Detection of Genetic Markers of Lung Cancer". The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
What is the current status of trial NCT00280202?
This trial is currently recruiting. The enrollment target is 6,000 participants. The study started on 1996-06. Estimated completion is 2050-12.
What conditions does trial NCT00280202 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00280202?
The interventions under investigation include: Biopsy of the major carinal area (PROCEDURE), Biopsy of abnormal & suspicious areas of the bronchial tree (PROCEDURE), Evaluation of the tumor for DNA mutations (PROCEDURE), Bronchoalveolar Lavage (BAL) for cytokine analysis (PROCEDURE), Correlation of flow cytometric & RT PCR for TNM stage (PROCEDURE).
Who is sponsoring clinical trial NCT00280202?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00280202 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.